Descripción de la empresa
Creative Medical Technology Holdings, Inc. operates as a commercial-stage biotechnology entity dedicated to developing novel biological therapeutics across specialized medical fields including immunotherapy, endocrinology, urology, neurology, and orthopedics within the United States. The company functions within the broader healthcare sector and specifically targets the biotechnology industry, a domain characterized by high research intensity and significant regulatory hurdles before products reach commercial viability. In terms of scale, the organization reports a market capitalization of $8.17M, generated annual revenue of $6,000 over the trailing twelve months, and maintains a workforce consisting of four employees. These valuation and operational metrics indicate that the company represents a micro-cap entity with minimal revenue generation relative to its market valuation, suggesting a business model heavily reliant on future asset appreciation or milestone payments rather than current commercial sales volumes to drive value.
Salud financiera
The company reports trailing twelve-month revenue of $6,000 alongside a net income of $-5,995,008 and an EBITDA of $-6,019,487, revealing a profound disconnect between top-line activity and bottom-line profitability. The substantial gap between the negligible revenue figure and the multi-million dollar net loss highlights an aggressive cost structure where operating expenses and research expenditures vastly outweigh current income streams. Free cash flow stands at $-3,751,198, indicating that the company is consuming cash reserves rapidly to fund its operations and development pipeline rather than generating internal liquidity. Despite the heavy cash burn, the balance sheet holds $7.21M in cash against a debt load of only $14,194, creating a scenario where liquidity far exceeds liability obligations. The debt-to-equity ratio of 0.19 further confirms that the company's capital structure is not leveraged, relying primarily on equity financing to sustain its financial position. Additionally, a current ratio of 25.97 suggests an extremely conservative approach to short-term liquidity, as current assets are more than twenty-five times current liabilities. Return on equity is reported at -86.5% and return on assets at -53.0%, metrics that reflect the inability of current operations to generate returns on the capital invested by shareholders or asset holders.
Evaluación de valoración
Valuation metrics for Creative Medical Technology Holdings, Inc. present a complex picture given the lack of earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -1.64. The absence of a trailing P/E ratio combined with a negative forward P/E implies that the market is pricing the stock based on non-earnings fundamentals, such as potential asset value or future clinical success, rather than current profitability. The price-to-book ratio sits at 1.09, indicating that the market values the company at just a 9% premium over its net asset book value, which is a conservative valuation for a biotechnology firm with proprietary assets. Alternative valuation multiples such as the price-to-sales ratio of 1361.61 and an EV/EBITDA of -0.16 suggest that the stock price is driven almost entirely by expectations of future growth rather than established sales performance. Regarding trading ranges, the 52-week high is $6.25 and the 52-week low is $1.50, providing a context for price volatility within the last year. The beta of 1.99 indicates that the stock price is highly sensitive to market movements, exhibiting nearly double the volatility of the broader market index.
Growth & Income
Revenue growth year-over-year is recorded at 0.0%, while earnings growth is N/A due to the persistent net losses, meaning there is currently no expansion in top-line activity or profitability to compare. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which aligns with the operational reality of a pre-profit biotechnology firm that must reinvest all available capital into research and development. Consequently, the firm does not distribute income to shareholders but instead retains earnings to fund its ongoing clinical trials and therapeutic development initiatives. This growth and income profile characterizes the asset as a pure-play speculative investment where total return potential relies exclusively on capital appreciation and successful product commercialization rather than dividend income or organic revenue expansion.